Jobe A H
Perinatal Research, Harbor-UCLA Medical Center, Torrance 90509.
J Perinatol. 1989 Mar;9(1):14-8.
Maternal corticosteroid treatments are used by many obstetric services in selected cases of preterm labor to induce lung maturation. This maturational strategy, however, has not received universal acceptance and often is used without much enthusiasm because such treatments do not prevent respiratory distress syndrome (RDS) in many infants. This article develops the thesis that the effects of maternal corticosteroid treatments are not primarily on the surfactant system, but rather on other aspects of lung development. The question posed by the title has not been answered by published clinical trials, but a growing body of experimental research with animal models indicates that strategies to induce lung maturation and to treat infants with surfactant will be complementary. An added benefit of the use of lung maturational agents should be the induction of maturational responses in other organ systems in the fetus.
许多产科服务机构在某些早产病例中使用母体皮质类固醇治疗来促进肺成熟。然而，这种成熟策略并未得到普遍认可，而且往往在缺乏热情的情况下使用，因为此类治疗无法预防许多婴儿的呼吸窘迫综合征（RDS）。本文提出这样一个论点，即母体皮质类固醇治疗的效果并非主要作用于表面活性剂系统，而是作用于肺发育的其他方面。已发表的临床试验尚未回答标题中提出的问题，但越来越多的动物模型实验研究表明，促进肺成熟的策略与用表面活性剂治疗婴儿将是相辅相成的。使用肺成熟剂的另一个好处应该是诱导胎儿其他器官系统产生成熟反应。
